GlassScriptPhysician profile
George Montgomery Baylor
NPI 1093806192
$23,808.23
in general payments reported to CMS, 2019-2025
49 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 89% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,455 · 2020: $2,115 · 2021: $2,536 · 2022: $2,724 · 2023: $4,584 · 2024: $3,294 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,585 · Travel and Lodging: $896 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $490 · Education: $7.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,584.65 |
| Travel and Lodging | $896.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $490.00 |
| Education | $7.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,789.27 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Medtronic USA, INC. | $6,465.20 | 2019-2020 | |
| Abbvie INC. | $1,167.40 | 2021-2025 | Qulipta, Ubrelvy |
| Boston Scientific Corporation | $1,107.44 | 2022-2025 | Intracept, Superion Indirect Decompression System, General - Pain Management |
| Nevro Corp. | $604.01 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $562.26 | 2019-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $467.77 | 2022-2025 | Proclaim, Eterna, Quantisal |
| Relievant Medsystems, INC. | $372.41 | 2020-2023 | Intracept |
| Pfizer INC. | $319.23 | 2020-2025 | |
| Ibsa Pharma INC. | $265.38 | 2023-2024 | Tirosint, Licart, Licart |
| Merz Pharmaceuticals, LLC | $214.09 | 2021-2025 | Xeomin |
| Amgen INC. | $212.89 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $199.00 | 2023-2025 | Exparel, Iovera, Zilretta |
| Depuy Synthes Sales INC. | $179.45 | 2021-2025 | Monovisc |
| Si-Bone, INC. | $150.85 | 2020-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Baylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.